IGC Pharma (IGC) Interest & Investment Income (2010 - 2017)
IGC Pharma (IGC) posted quarterly Interest & Investment Income of $100.0 for Q3 2017, down 12.28% year-over-year from $114.0 in Q3 2016, and down 12.28% quarter-over-quarter from $114.0 in Q3 2016.
IGC Pharma (IGC) Interest & Investment Income (2010 - 2017) Analysis & Trends
IGC Pharma (IGC) has reported Interest & Investment Income for 8 consecutive years, with $100.0 the latest figure, recorded in Q3 2017.
- In Q3 2017, Interest & Investment Income fell 12.28% year-over-year to $100.0; the TTM figure through Sep 2017 stood at $2228.0 (up 1.36% YoY), while the FY2017 annual figure was $1744.0, down 16.35% from the prior year.
- Interest & Investment Income retreated to $100.0 in Q3 2017 per IGC's latest filing, from $114.0 in the prior quarter.
- Across five years, Interest & Investment Income topped out at $27509.0 in Q1 2013 and bottomed at $70.0 in Q4 2015.
- Historically, Interest & Investment Income has averaged $3572.3 across 5 years, with a median of $1919.0 in 2013.
- Annual changes were most pronounced in 2013 — Interest & Investment Income jumped 387.46% — and 2015, when it tumbled 95.65%.
- IGC Pharma's Interest & Investment Income stood at $1824.0 in 2013, then dropped by 11.73% to $1610.0 in 2014, then sank by 95.65% to $70.0 in 2015, then surged by 62.86% to $114.0 in 2016, then declined by 12.28% to $100.0 in 2017.
- Business Quant data shows IGC's Interest & Investment Income at $100.0 in Q3 2017, $114.0 in Q3 2016, and $2014.0 in Q1 2016.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 120.60 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | -48.00 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 48.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 67.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 27.90 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 28.14 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 10.98 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 5.13 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 115.94 Mn |
| 10 | IGC Pharma | 27.20 Mn | 26.94 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2017 | 100.00 |
| Sep 30, 2016 | 114.00 |
| Mar 31, 2016 | 2,014.00 |
| Dec 31, 2015 | 70.00 |
| Jun 30, 2015 | 694.00 |
| Mar 31, 2015 | 2,715.00 |
| Dec 31, 2014 | 1,610.00 |
| Sep 30, 2014 | 136.00 |
| Jun 30, 2014 | 2,338.00 |
| Mar 31, 2014 | 4,555.00 |
| Dec 31, 2013 | 1,824.00 |
| Sep 30, 2013 | 2,253.00 |
| Jun 30, 2013 | 4,080.00 |
| Mar 31, 2013 | 27,509.00 |
| Dec 31, 2012 | 2,051.00 |
| Jun 30, 2012 | 837.00 |
| Mar 31, 2012 | 81,131.00 |
| Dec 31, 2011 | 59,629.00 |
| Sep 30, 2011 | 59,085.00 |
| Jun 30, 2011 | 67,348.00 |